North East and North Cumbria
ICS Formulary
 
back
4 Central nervous system
04-12 Miscellaneous

Dehydrated alcohol 100% BP for Injection
Formulary
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients

Red View adult BNF  View SPC online  View childrens BNF
Eplontersen  Wainzua®
Formulary
  • 45 mg solution for injection in pre-filled pen
  • Approved as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy in line with NICE
Link  NICE TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Inotersen  Tegsedi®
Formulary

  • Approved as an option for treating stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis in line with NICE
Link   NICE Highly specialised technologies 9: Inotersen for treating hereditary transthyretin amyloidosis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Patisiran Onpattro®
Formulary

  • 10mg vial 

  • Approved for the treatment of hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuopathy in line with NICE
Link  NICE Highly specialised technologies 10: Patisiran for treating hereditary transthyretin amyloidosis

Red View adult BNF  View SPC online  View childrens BNF  HCD
Phenol 5% in Glycerol Injection
Formulary
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients

Red View adult BNF  View SPC online  View childrens BNF
Tafamidis  Vyndaqel®
Formulary
  • 61 mg soft capsules
  • Approved for for treating transthyretin amyloidosis with cardiomyopathy in line with NICE
Link  NICE TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

Red View adult BNF  View SPC online  View childrens BNF  HCD
Vutrisiran Amvuttra®
Formulary
  • Approved as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy - in line with NICE TA868.
  • Summer 2023 - Only one centre in London commissioned to provide this drug for patients in England.
Link  NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis

Red View adult BNF  View SPC online  View childrens BNF